| REVIEW ARTICLE |
|
| Year : 2012 | Volume
: 16
| Issue : 3 | Page : 343-348 |
|
|
Teriparatide - Indications beyond osteoporosis
Marilyn Lee Cheng1, Vishal Gupta2
1 Department of Endocrinology, Khoo Teck Puat Hospital, 90 Yishun Central, Singapore
2 Department of Endocrinology, Jaslok Hospital and Research Centre, Mumbai, India
Correspondence Address:
Vishal Gupta
Department of Endocrinology, Jaslok Hospital and Research Centre, 15, Dr. Deshmukh Marg, Pedder Road, Mumbai
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.95661
|
|
|
Osteoporosis is a condition of impaired bone strength that results in an increased risk of fracture. The current and most popular pharmacological options for the treatment of osteoporosis include antiresorptive therapy, in particular, oral bisphosphonates (alendronate, risedronate, ibandronate). Anabolic agents like teriparatide have widened our therapeutic options. They act by directly stimulating bone formation and improving bone mass quantity and quality. Two forms of recombinant human parathyroid hormone (PTH) are available : full-length PTH (PTH 1-84; approved in the EU only) and the 1-34 N-terminal active fragment of PTH (teriparatide, US FDA approved). This review aims to discuss the benefits of teriparatide beyond the currently licensed indications like fracture healing, dental stability, osteonecrosis of jaw, hypoparathyroidism, and hypocalcemia. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
